164 related articles for article (PubMed ID: 34586539)
1. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [
Ghai A; Fettig N; Fontana F; DiPersio J; Rettig M; Neal JO; Achilefu S; Shoghi KI; Shokeen M
EJNMMI Res; 2021 Sep; 11(1):97. PubMed ID: 34586539
[TBL] [Abstract][Full Text] [Related]
2. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D; Zhou H; Beaino W; Lu L; Rettig M; Snee M; Skeath J; DiPersio JF; Akers WJ; Laforest R; Anderson CJ; Tomasson MH; Shokeen M
J Nucl Med; 2016 Apr; 57(4):640-5. PubMed ID: 26742713
[TBL] [Abstract][Full Text] [Related]
3. First-in-Humans Evaluation of Safety and Dosimetry of
Laforest R; Ghai A; Fraum TJ; Oyama R; Frye J; Kaemmerer H; Gaehle G; Voller T; Mpoy C; Rogers BE; Fiala M; Shoghi KI; Achilefu S; Rettig M; Vij R; DiPersio JF; Schwarz S; Shokeen M; Dehdashti F
J Nucl Med; 2023 Feb; 64(2):320-328. PubMed ID: 36008121
[TBL] [Abstract][Full Text] [Related]
4. PET Imaging of VLA-4 in a New BRAF
Bellavia MC; Nyiranshuti L; Latoche JD; Ho KV; Fecek RJ; Taylor JL; Day KE; Nigam S; Pun M; Gallazzi F; Edinger RS; Storkus WJ; Patel RB; Anderson CJ
Mol Imaging Biol; 2022 Jun; 24(3):425-433. PubMed ID: 34694528
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging of very late antigen-4 (α4β1 integrin) in the premetastatic niche.
Shokeen M; Zheleznyak A; Wilson JM; Jiang M; Liu R; Ferdani R; Lam KS; Schwarz JK; Anderson CJ
J Nucl Med; 2012 May; 53(5):779-86. PubMed ID: 22496586
[TBL] [Abstract][Full Text] [Related]
6. Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
Soodgupta D; Hurchla MA; Jiang M; Zheleznyak A; Weilbaecher KN; Anderson CJ; Tomasson MH; Shokeen M
PLoS One; 2013; 8(2):e55841. PubMed ID: 23409060
[TBL] [Abstract][Full Text] [Related]
7. A Metal-Free DOTA-Conjugated
Roxin Á; Zhang C; Huh S; Lepage M; Zhang Z; Lin KS; Bénard F; Perrin DM
Bioconjug Chem; 2019 Apr; 30(4):1210-1219. PubMed ID: 30896929
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of
Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
[TBL] [Abstract][Full Text] [Related]
9. Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis.
Zhu Q; Barnes CE; Mannes PZ; Latoche JD; Day KE; Nedrow JR; Novelli EM; Anderson CJ; Tavakoli S
EJNMMI Res; 2023 Jun; 13(1):55. PubMed ID: 37273103
[TBL] [Abstract][Full Text] [Related]
10. Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells.
Mattila JT; Beaino W; Maiello P; Coleman MT; White AG; Scanga CA; Flynn JL; Anderson CJ
J Immunol; 2017 Jul; 199(2):806-815. PubMed ID: 28592427
[TBL] [Abstract][Full Text] [Related]
11. 111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.
Denardo SJ; Liu R; Albrecht H; Natarajan A; Sutcliffe JL; Anderson C; Peng L; Ferdani R; Cherry SR; Lam KS
J Nucl Med; 2009 Apr; 50(4):625-34. PubMed ID: 19289419
[TBL] [Abstract][Full Text] [Related]
12. Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival.
Hathi D; Chanswangphuwana C; Cho N; Fontana F; Maji D; Ritchey J; O'Neal J; Ghai A; Duncan K; Akers WJ; Fiala M; Vij R; DiPersio JF; Rettig M; Shokeen M
Sci Rep; 2022 Jan; 12(1):30. PubMed ID: 34996933
[TBL] [Abstract][Full Text] [Related]
13. Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined
Sachpekidis C; Goldschmidt H; Kopka K; Kopp-Schneider A; Dimitrakopoulou-Strauss A
EJNMMI Res; 2018 Apr; 8(1):28. PubMed ID: 29633046
[TBL] [Abstract][Full Text] [Related]
14. 11C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma.
Lückerath K; Lapa C; Albert C; Herrmann K; Jörg G; Samnick S; Einsele H; Knop S; Buck AK
Oncotarget; 2015 Apr; 6(10):8418-29. PubMed ID: 25762625
[TBL] [Abstract][Full Text] [Related]
15. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
16. Current and Future PET Imaging for Multiple Myeloma.
Ishibashi M; Takahashi M; Yamaya T; Imai Y
Life (Basel); 2023 Aug; 13(8):. PubMed ID: 37629558
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. [
Valtorta S; Toscani D; Chiu M; Sartori A; Coliva A; Brevi A; Taurino G; Grioni M; Ruffini L; Vacondio F; Zanardi F; Bellone M; Moresco RM; Bussolati O; Giuliani N
Front Oncol; 2021; 11():760732. PubMed ID: 34712616
[TBL] [Abstract][Full Text] [Related]
19. PET/MR imaging and optical imaging of metastatic rhabdomyosarcoma in mice.
Armeanu-Ebinger S; Griessinger CM; Herrmann D; Fuchs J; Kneilling M; Pichler BJ; Seitz G
J Nucl Med; 2014 Sep; 55(9):1545-51. PubMed ID: 24963126
[TBL] [Abstract][Full Text] [Related]
20. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
